Systemic Antifungals Market Size, Share, By Drug Classes (Azoles, Echinocandins, Polyenes, and Others), Indication (Aspergillosis, Histoplasmosis, Gastrointestinal Candidiasis, Blastomycosis, Fungal Endocarditis, and Others), End-Users (Hospital & Specialty Clinics, Ambulatory Surgical Centers, Research Institute & Clinical Trial Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• GSK plc
• BAYER AG
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Enzon Pharmaceuticals, Inc.
•  SCYNEXIS, Inc.
• Novartis AG
• Xian Janssen Pharmaceutical Ltd.
• AdvaCare Pharma
• Yangtze Energy Technologies, Inc.
• Ion Power, Inc.
• Ensinger

Recent News:

• Fresenius Kabi announced that it has introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system in January 2024. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules.
• Pharma major Cadila Pharmaceuticals has launched a new triazole antifungal drug Posaconazole, which has been found to be effective against a wide range of invasive fungal disease In July 2021. The drug has also been recommended as a second line treatment for Mucormycosis or black fungus as it is commonly known.